MutL homolog 1 contributes to temozolomide-induced autophagy via ataxia-telangiectasia mutated in glioma

Molecular Medicine Reports

Volumn 11, Issue 6, 2015, Pages 4591-4596

  Zou, Yuhui ^a,b   Wang, Qiong ^a   Wang, Weimin ^a  

^a GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

^b People's Liberation Army No425 Hospital   (China)

Author keywords

Ataxia telangiectasia mutated; Autophagy; Glioma; MutL homolog 1; Temozolomide

Indexed keywords

FLUORESCENT DYE; LIPOFECTAMINE; MICRORNA 21; 2-MORPHOLIN-4-YL-6-THIANTHREN-1-YL-PYRAN-4-ONE; ALKYLATING AGENT; ATM PROTEIN; DACARBAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MLH1 PROTEIN, HUMAN; MORPHOLINE DERIVATIVE; NUCLEAR PROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRONE DERIVATIVE; SIGNAL PEPTIDE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SMALL INTERFERING RNA; TEMOZOLOMIDE; ULK1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE MICROSCOPE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION; SPROUTY HOMOLOG 2 GENE; U266 CELL LINE; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; AUTOPHAGY; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; GLIOMA; METABOLISM; PHOSPHORYLATION; RNA INTERFERENCE; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMP-ACTIVATED PROTEIN KINASES; ANTINEOPLASTIC AGENTS, ALKYLATING; ATAXIA TELANGIECTASIA MUTATED PROTEINS; AUTOPHAGY; CELL LINE, TUMOR; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; GLIOMA; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MORPHOLINES; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRONES; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84924690437     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3293     Document Type: Article

References (26)

1. Cen L, Carlson BL, Pokorny JL, et al: Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models. Neuro Oncol 15: 735-746, 2013.
2. Jiang G, Li LT, Xin Y, Zhang L, Liu YQ and Zheng JN: Strategies to improve the killing of tumors using temozolomide: targeting the DNA repair protein MGMT. Curr Med Chem 19: 3886-3892, 2012.
3. Zhang J, Stevens MF and Bradshaw TD: Temozolomide: Mechanisms of action, repair and resistance. Curr Mol Pharmacol 5: 102-114, 2012.
4. Skiriute D, Vaitkiene P, Saferis V, et al: MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma. BMC Cancer 12: 218, 2012.
5. Felsberg J, Thon N, Eigenbrod S, et al: Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer 129: 659-670, 2011.
6. Lin CJ, Lee CC, Shih YL, et al: Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. Free Radic Biol Med 52: 377-391, 2012.
7. Katayama M, Kawaguchi T, Berger MS and Pieper RO: DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ 14: 548-558, 2007.
8. Natsumeda M, Aoki H, Miyahara H, et al: Induction of autophagy in temozolomide treated malignant gliomas. Neuropathology 31: 486-493, 2011.
9. Wong PM, Puente C, Ganley IG and Jiang X: The ULK1 complex: sensing nutrient signals for autophagy activation. Autophagy 9: 124-137, 2013.
10. She C, Zhu LQ, Zhen YF, Wang XD and Dong QR: Activation of AMPK protects against hydrogen peroxide-induced osteoblast apoptosis through autophagy induction and NADPH maintenance: New implications for osteonecrosis treatment? Cell Signal 26: 1-8, 2014.
11. Singh K, Matsuyama S, Drazba JA and Almasan A: Autophagy-dependent senescence in response to DNA damage and chronic apoptotic stress. Autophagy 8: 236-251, 2012.
12. Duan X, Ponomareva L, Veeranki S and Choubey D: IFI16 induction by glucose restriction in human fibroblasts contributes to autophagy through activation of the ATM/AMPK/p53 pathway. PLoS One 6: e19532, 2011.
13. Brieger A, Adam R, Passmann S, Plotz G, Zeuzem S and Trojan J: A CRM1-dependent nuclear export pathway is involved in the regulation of MutLalpha subcellular localization. Genes Chromosomes Cancer 50: 59-70, 2011.
14. Takahashi A and Ohnishi T: Does gammaH2AX foci formation depend on the presence of DNA double strand breaks? Cancer Lett 229: 171-179, 2005.
15. Murrow L and Debnath J: Autophagy as a stress-response and quality-control mechanism: Implications for cell injury and human disease. Annu Rev Pathol 8: 105-137, 2013.
16. Wu J, Dang Y, Su W, et al: Molecular cloning and characterization of rat LC3A and LC3B-two novel markers of autophagosome. Biochem Biophys Res Commun 339: 437-442, 2006.
17. Zeng X and Kinsella TJ: BNIP3 is essential for mediating 6-thioguanine-and 5-fluorouracil-induced autophagy following DNA mismatch repair processing. Cell Res 20: 665-675, 2010.
18. Zeng X and Kinsella TJ: Mammalian target of rapamycin and S6 kinase 1 positively regulate 6-thioguanine-induced autophagy. Cancer Res 68: 2384-2390, 2008.
19. Zeng X and Kinsella TJ: A novel role for DNA mismatch repair and the autophagic processing of chemotherapy drugs in human tumor cells. Autophagy 3: 368-370, 2007.
20. Johnson JR, Erdeniz N, Nguyen M, Dudley S and Liskay RM: Conservation of functional asymmetry in the mammalian MutLalpha ATPase. DNA Repair (Amst) 9: 1209-1213, 2010.
21. Polosina YY and Cupples CG: MutL: conducting the cell's response to mismatched and misaligned DNA. Bioessays 32: 51-59, 2010.
22. Chahwan R, van Oers JM, Avdievich E, et al: The ATPase activity of MLH1 is required to orchestrate DNA double-strand breaks and end processing during class switch recombination. J Exp Med 209: 671-678, 2012.
23. Quiros S, Roos WP and Kaina B: Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles. Cell Cycle 9: 168-178, 2010.
24. Sarkaria JN, Kitange GJ, James CD, et al: Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res 14: 2900-2908, 2008.
25. Taverna P, Liu L, Hanson AJ, Monks A and Gerson SL: Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen. Cancer Chemother Pharmacol 46: 507-516, 2000.
26. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y and Kondo S: Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 11: 448-457, 2004.